Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389274 | 0.87 | GPR119 (0.57) | GPR119CYP3A4CYP2C19KCNH2 | |
| SCHEMBL5072828 | 0.83 | GPR119 (0.52) | GPR119CYP3A4CYP2C19KCNH2 | |
| SCHEMBL5203459 | 0.81 | GPR119 (0.50) | GPR119CYP3A4CYP2C19GPR183 | |
| SCHEMBL386417 | 0.80 | GPR119 (0.58) | GPR119CYP3A4CYP2C19KCNH2 | |
| SCHEMBL390430 | 0.80 | GPR119 (0.59) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL390524 | 0.79 | GPR119 (0.54) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL386414 | 0.78 | GPR119 (0.72) | GPR119CYP3A4CYP2C19KCNH2GPR183 | |
| SCHEMBL388524 | 0.77 | GPR119 (0.63) | GPR119CYP3A4CYP2C19KCNH2 | |
| SCHEMBL5203446 | 0.77 | GPR119 (0.49) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL389339 | 0.76 | GPR119 (0.58) | GPR119CYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |